The ER proteostasis network in ALS: Determining the differential motoneuron vulnerability

Neuroscience Letters

Volumn 636, Issue , 2017, Pages 9-15

  Rozas, Pablo ^a,b,c   Bargsted, Leslie ^a,b,c   Martínez, Francisca ^a,b,c   Hetz, Claudio ^a,b,c,d,e   Medinas, Danilo B ^a,b,c  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c Universidad de Chile and Geroscience Center for Brain Health and Metabolism   (Chile)

^d BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ALS; Chaperones; ER stress; Proteostasis; Selective vulnerability

Indexed keywords

CHAPERONE; PROTEIN AGGREGATE; PROTEOME;

AMYOTROPHIC LATERAL SCLEROSIS; ENDOPLASMIC RETICULUM; HUMAN; MOTONEURON; MUSCLE INNERVATION; NERVE CELL DIFFERENTIATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; REVIEW; UNFOLDED PROTEIN RESPONSE; ANIMAL; ENDOPLASMIC RETICULUM STRESS; INNERVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN FOLDING; SKELETAL MUSCLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMANS; MOLECULAR CHAPERONES; MOTOR NEURONS; MUSCLE, SKELETAL; PROTEIN AGGREGATES; PROTEIN FOLDING; PROTEOME;

EID: 84975516571     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.04.066     Document Type: Review

References (99)

1. [1] Pasinelli, P., Brown, R., Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7:9 (2006), 710–723.
2. [2] Saxena, S., Caroni, P., Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 71:1 (2011), 35–48.
3. [3] Leblond, C.S., et al. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 262 (2014), 91–101.
4. [4] Peters, O.M., Ghasemi, M., Brown, R.H., Emerging mechanisms of molecular pathology in ALS. J. Clin. Invest., 125(6), 2015, 2548.
5. [5] Ling, S.-C.C., Polymenidou, M., Cleveland, D.W., Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79:3 (2013), 416–438.
6. [6] Li, Y.R., et al. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201:3 (2013), 361–372.
7. [7] Laird, F.M., et al. Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J. Neurosci. 28:9 (2008), 1997–2005.
8. [8] Landers, J.E., et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 106:22 (2009), 9004–9009.
9. [9] Manfredi, G., Kawamata, H., Mitochondria and endoplasmic reticulum crosstalk in amyotrophic lateral sclerosis. Neurobiol. Dis. 90 (2015), 35–42.
10. [10] Matus, S., et al. ER dysfunction and protein folding stress in ALS. Int. J. Cell Biol. 2013 (2013), 1–12.
11. [11] Turner, M.R., et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 14:Suppl. 1 (2013), 19–32.
12. [12] Wang, M., Kaufman, R.J., The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14:9 (2014), 581–597.
13. [13] Walter, P., Ron, D., The unfolded protein response: from stress pathway to homeostatic regulation. Science 334:6059 (2011), 1081–1086.
14. [14] Oakes, S.A., Papa, F.R., The role of endoplasmic reticulum stress in human pathology. Annu. Rev. Pathol.: Mech. Dis. 10:1 (2015), 1–22.
15. [15] Urra, H., et al. When ER stress reaches a dead end. Biochim. Biophys. Acta (BBA)—Mol. Cell Res. 1833:12 (2013), 3507–3517.
16. [16] Ruegsegger, C., Saxena, S., Proteostasis impairment in ALS. Brain Res., 2016, 10.1016/j.brainres.2016.03.032 (in press).
17. [17] Parakh, S., Atkin, J.D., Protein folding alterations in amyotrophic lateral sclerosis. Brain Res., 2016, 10.1016/j.brainres.2016.04.010 (in press).
18. [18] Atkin, J., et al. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol. Dis. 30:3 (2008), 400–407.
19. [19] Hetz, C., et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 23:19 (2009), 2294–2306.
20. [20] Ilieva, H., Polymenidou, M., Cleveland, D.W., Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187:6 (2009), 761–772.
21. [21] Nagai, M., et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 10:5 (2007), 615–622.
22. [22] Haidet-Phillips, A.M., et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29:9 (2011), 824–828.
23. [23] Yamanaka, K., et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 11:3 (2008), 251–253.
24. [24] Kang, S.H., et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 16:5 (2013), 571–579.
25. [25] Boillée, S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science (New York, N.Y.) 312:5778 (2006), 1389–1392.
26. [26] Wong, M., Martin, L.J., Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum. Mol. Genet. 19:11 (2010), 2284–2302.
27. [27] Sun, S., et al. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proc. Natl. Acad. Sci., 112(50), 2015.
28. [28] Saxena, S., Cabuy, E., Caroni, P., A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat. Neurosci. 12:5 (2009), 627–636.
29. [29] Dirren, E., et al. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann. Clin. Transl. Neurol. 2:2 (2015), 167–184.
30. [30] Pun, S., et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 9:3 (2006), 408–419.
31. [31] de L'Etang, A., et al. Marinesco-Sjögren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS. Nat. Neurosci. 18:2 (2015), 227–238.
32. [32] Ng, S.-Y., et al. Genome-wide RNA-Seq of human motor neurons implicates selective ER stress activation in spinal muscular atrophy. Cell Stem Cell 17:5 (2015), 569–584.
33. [33] Matus, S., Medinas, D.B., Hetz, C., Common ground: stem cell approaches find shared pathways underlying ALS. Cell Stem Cell 14:6 (2014), 697–699.
34. [34] Kiskinis, E., et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 14:6 (2014), 781–795.
35. [35] Saxena, S., et al. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron 80:1 (2013), 80–96.
36. [36] King, A.E., et al. Excitotoxicity in ALS: overstimulation, or overreaction?. Exp. Neurol. 275 (2016), 162–171.
37. [37] Zhao, L., et al. Protein accumulation and neurodegeneration in the woozy mutant mouse is caused by disruption of SIL1: a cochaperone of BiP. Nat. Genet. 37:9 (2005), 974–979.
38. [38] Prudencio, M., et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat. Neurosci. 18:8 (2015), 1175–1182.
39. [39] Manfredi, G., Kawamata, H., Mitochondria and endoplasmic reticulum crosstalk in amyotrophic lateral sclerosis. Neurobiol. Dis. 90 (2016), 35–42.
40. [40] Mavlyutov, T.A., Epstein, M.L., Andersen, K.A., The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 167:2 (2010), 247–255.
41. [41] Mavlyutov, T.A., et al. Role of the sigma-1 receptor in amyotrophic lateral sclerosis (ALS). J. Pharmacol. Sci. 127:1 (2015), 10–16.
42. [42] Al-Saif, A., Al-Mohanna, F., Bohlega, S., A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol. 70:6 (2011), 913–919.
43. [43] Ruscher, K., Wieloch, T., The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration. J. Pharmacol. Sci. 127:1 (2015), 30–35.
44. [44] Mavlyutov, T.A., et al. Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience 240 (2013), 129–134.
45. [45] Velde, C., et al. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl. Acad. Sci. 105:10 (2008), 4022–4027.
46. [46] Liu, J., et al. Toxicity of familial ALS-Linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 43:1 (2004), 5–17.
47. [47] Nishitoh, H., et al. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 22:11 (2008), 1451–1464.
48. [48] Israelson, A., et al. Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron 86:1 (2015), 218–232.
49. [49] Kaplan, A., et al. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron 81:2 (2014), 333–348.
50. [50] Atkin, J., et al. Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J. Biol. Chem. 281:40 (2006), 30152–30165.
51. [51] Ilieva, E.V., et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain: J. Neurol. 130:Pt 12 (2007), 3111–3123.
52. [52] Atkin, J.D., et al. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol. Dis. 30:3 (2008), 400–407.
53. [53] Nardo, G., et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One, 6(10), 2011.
54. [54] Jin, H., et al. Late-onset of spinal neurodegeneration in knock-In mice expressing a mutant BiP. PLoS One, 9(11), 2014.
55. [55] Bosco, D.A., et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 13:11 (2010), 1396–1403.
56. [56] Bernard-Marissal, N., et al. Reduced calreticulin levels link endoplasmic reticulum stress and Fas-triggered cell death in motoneurons vulnerable to ALS. J. Neurosci. 32:14 (2012), 4901–4912.
57. [57] Bernard-Marissal, N., et al. Calreticulin levels determine onset of early muscle denervation by fast motoneurons of ALS model mice. Neurobiol. Dis. 73 (2015), 130–136.
58. [58] Feige, M.J., Hendershot, L.M., Disulfide bonds in ER protein folding and homeostasis. Curr. Opin. Cell Biol. 23:2 (2011), 167–175.
59. [59] Appenzeller-Herzog, C., Ellgaard, L., The human PDI family: versatility packed into a single fold. Biochim. Biophys. Acta 1783:4 (2008), 535–548.
60. [60] Walker, A.K., et al. ALS-Associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS One, 8(11), 2013.
61. [61] Farg, M.A., et al. Mutant FUS induces endoplasmic reticulum stress in amyotrophic lateral sclerosis and interacts with protein disulfide-isomerase. Neurobiol. Aging 33:12 (2012), 2855–2868.
62. [62] Kwok, C., et al. Association studies indicate that protein disulfide isomerase is a risk factor in amyotrophic lateral sclerosis. Free Radic. Biol. Med. 58 (2013), 81–86.
63. [63] Yang, Q., Guo, Z.-B.B., Polymorphisms in protein disulfide isomerase are associated with sporadic amyotrophic lateral sclerosis in the Chinese Han population. Int. J. Neurosci. 2015 (2016), 1–5.
64. [64] Gonzalez-Perez, P., et al. Identification of rare protein disulfide isomerase gene variants in amyotrophic lateral sclerosis patients. Gene 566:2 (2015), 158–165.
65. [65] Woehlbier, U., et al. ALS-linked protein disulfide isomerase variants cause motor dysfunction. EMBO J. 35:8 (2016), 845–865.
66. [66] Torres, M., et al. The protein-disulfide isomerase ERp57 regulates the steady-state levels of the prion protein. J. Biol. Chem. 290:39 (2015), 23631–23645.
67. [67] Castillo, V., et al. Functional role of the disulfide isomerase ERp57 in axonal regeneration. PLoS One, 10(9), 2015.
68. [68] Fritz, E., et al. Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. J. Neurophysiol. 109:11 (2013), 2803–2814.
69. 2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur.J. Neurosci. 27:10 (2008), 2501–2514.
70. [70] Miller, R.G., Mitchell, J.D., Moore, D.H., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). The Cochrane database of systematic reviews, 2012, 3.
71. [71] van Zundert, B., et al. Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J. Cell. Biochem. 113:11 (2012), 3301–3312.
72. [72] Hetz, C., Chevet, E., Harding, H.P., Targeting the unfolded protein response in disease. Nat. Rev. Drug Discov. 12:9 (2013), 703–719.
73. [73] Hetz, C., Mollereau, B., Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat. Rev. Neurosci. 15:4 (2014), 233–249.
74. [74] Freeman, O.J., Mallucci, G.R., The UPR and synaptic dysfunction in neurodegeneration. Brain Res., 2016, 10.1016/j.brainres.2016.03.029 (in press).
75. [75] Mollereau, B., et al. Adaptive preconditioning in neurological diseases −Therapeutic insights from proteostatic perturbations. Brain Res., 2016, 10.1016/j.brainres.2016.02.033 (in press).
76. [76] Fouillet, A., et al. ER stress inhibits neuronal death by promoting autophagy. Autophagy 8:6 (2012), 877–888.
77. [77] Matus, S., Castillo, K., Hetz, C., Hormesis protecting neurons against cellular stress in Parkinson disease. Autophagy 8:6 (2012), 997–1001.
78. [78] Das, I., et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 348:6231 (2015), 239–242.
79. [79] Vaccaro, A., et al. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiol. Dis. 55 (2013), 64–75.
80. [80] Vieira, F.G., et al. Guanabenz treatment accelerates disease in a mutant SOD1 mouse model of ALS. PLoS One, 10(8), 2015.
81. [81] Gorbatyuk, M.S., et al. Glucose regulated protein 78 diminishes α-Synuclein neurotoxicity in a rat model of parkinson disease. Mol. Ther. 20:7 (2012), 1327–1337.
82. [82] Gorbatyuk, M.S., et al. Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc. Natl. Acad. Sci. 107:13 (2010), 5961–5966.
83. [83] Zuleta, A., et al. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease. Biochem. Biophys. Res. Commun. 420:3 (2012), 558–563.
84. [84] Valdés, P., et al. Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc. Natl. Acad. Sci. 111:18 (2014), 6804–6809.
85. [85] Valenzuela, V.et al., Activation of the unfolded protein response enhances motor recovery after spinal cord injury. Cell Death Dis., 3(2), 2012, 272.
86. [86] Oñate, M., et al. Activation of the unfolded protein response promotes axonal regeneration after peripheral nerve injury. Sci. Rep., 6, 2016, 21709.
87. [87] Martínez, G., et al. Regulation of memory formation by the transcription factor XBP1. Cell Rep. 14:6 (2016), 1382–1394.
88. [88] Toldo, S., et al. Chapter three the role of PDI as a survival factor in cardiomyocyte ischemia. Methods Enzymol. 489 (2011), 47–65.
89. [89] Bray, N., Neurodegenerative disease: searching for the weak spots. Nat. Rev. Drug Discov. 13:4 (2014), 256–257.
90. [90] Hoecke, A., et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 18:9 (2012), 1418–1422.
91. [91] Zhang, Y.-J.J., et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. (Berl.) 128:4 (2014), 505–524.
92. [92] Elia, A.E., et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 23:1 (2016), 45–52.
93. [93] Ryu, H., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93:5 (2005), 1087–1098.
94. [94] Cudkowicz, M.E., et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral Scler. 10:2 (2009), 99–106.
95. [95] Li, Y., et al. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model. Neuroscience 298 (2015), 12–25.
96. [96] Zhang, X., et al. MTOR-independent: autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy 10:4 (2014), 588–602.
97. [97] Castillo, K., et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 9:9 (2013), 1308–1320.
98. [98] Vidal, R.L., et al. Targeting autophagy in neurodegenerative diseases. Trends Pharmacol. Sci. 35:11 (2014), 583–591.
99. [99] Mardones, P., Martínez, G., Hetz, C., Control of systemic proteostasis by the nervous system. Trends Cell Biol. 25:1 (2015), 1–10.